Novel chimeric antigen receptors for the effective and safe treatment of NY-BR-1 positive breast cancer.

Autor: Jäger D; Department of Medical Oncology, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany.; Clinical Cooperation Unit 'Applied Tumor Immunity', German Cancer Research Center (DKFZ), Heidelberg, Germany., Berger A; Clinical Cooperation Unit 'Applied Tumor Immunity', German Cancer Research Center (DKFZ), Heidelberg, Germany., Tuch A; Clinical Cooperation Unit 'Applied Tumor Immunity', German Cancer Research Center (DKFZ), Heidelberg, Germany., Luckner-Minden C; Department of Medical Oncology, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany., Eurich R; Department of Medical Oncology, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany., Hlevnjak M; Computational Oncology Group, Molecular Precision Oncology Program, NCT and DKFZ, Heidelberg, Germany., Schneeweiss A; Division of Gynecological Oncology, NCT, University Hospital Heidelberg, Heidelberg, Germany.; Division of Molecular Genetics, DKFZ, Heidelberg, Germany.; NCT Heidelberg, a partnership between DKFZ and Heidelberg University Medical Center, Heidelberg, Germany., Lichter P; German Cancer Consortium (DKTK), Heidelberg, Germany., Aulmann S; Institute for Pathology, University Hospital Heidelberg, Heidelberg, Germany., Heussel CP; Department of Diagnostics and Interventional Radiology, Thoraxklinik Heidelberg, University Hospital Heidelberg, Heidelberg, Germany., Fremd C; Department of Medical Oncology, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany.; Division of Gynecological Oncology, NCT, University Hospital Heidelberg, Heidelberg, Germany.; Division of Molecular Genetics, DKFZ, Heidelberg, Germany.; NCT Heidelberg, a partnership between DKFZ and Heidelberg University Medical Center, Heidelberg, Germany., Harbottle R; DNA Vector Lab, DKFZ, Heidelberg, Germany.; GMP and T Cell Therapy Group, DKFZ, Heidelberg, Germany., Zörnig I; Department of Medical Oncology, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany., Schmidt P; Department of Medical Oncology, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany.; DNA Vector Lab, DKFZ, Heidelberg, Germany.

Publikováno v: Clinical and translational medicine [Clin Transl Med] 2024 Jul; Vol. 14 (7), pp. e1776.

1126P Prediction of clinical outcome by soluble immune checkpoints and T cell subsets in patients treated with immune checkpoint blockers for metastasized melanoma

Autor: Hassel, J.C., Wiecken, M., Hülsmeyer, I., Roth, J., Eurich, R., Machiraju, D.

Publikováno v: In Annals of Oncology September 2020 31 Supplement 4:S756-S757

CCR5 status and metastatic progression in colorectal cancer.

Autor: Suarez-Carmona M; Department of Translational Immunotherapy, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Medical oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.; Helmholtz Center for Translational Oncology (HITRON), Mainz, Germany., Chaorentong P; Clinical Cooperation Unit Applied Tumor Immunity, National Center for Tumor Diseases, German Cancer Research Center, Heidelberg, Germany., Kather JN; Medical oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.; Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany., Rothenheber R; Medical oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany., Ahmed A; Medical oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany., Berthel A; Medical oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany., Heinzelmann A; Medical oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany., Moraleda R; Medical oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.; Clinical Cooperation Unit Applied Tumor Immunity, National Center for Tumor Diseases, German Cancer Research Center, Heidelberg, Germany., Valous NA; Clinical Cooperation Unit Applied Tumor Immunity, National Center for Tumor Diseases, German Cancer Research Center, Heidelberg, Germany., Kosaloglu Z; Clinical Cooperation Unit Applied Tumor Immunity, National Center for Tumor Diseases, German Cancer Research Center, Heidelberg, Germany., Eurich R; Medical oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany., Wolf J; Medical oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany., Grauling-Halama S; Department of Translational Immunotherapy, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Medical oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.; Helmholtz Center for Translational Oncology (HITRON), Mainz, Germany., Hundemer M; Department of Hematology, University Hospital Heidelberg, Heidelberg, Germany., Lasitschka F; Institute for Pathology, University Hospital Heidelberg, Heidelberg, Germany., Klupp F; Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany., Kahlert C; Department of Surgery, University Hospital Dresden, Dresden, Germany., Ulrich A; Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany., Schneider M; Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany., Falk C; Institute of Transplant Immunology, Integrated Research and Treatment Center Transplantation, Hannover Medical School Hannover, Hanover, Germany., Jäger D; Medical oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.; Helmholtz Center for Translational Oncology (HITRON), Mainz, Germany.; Department of Internal Medicine VI, University Hospital Heidelberg, Heidelberg, Germany., Zoernig I; Medical oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.; Clinical Cooperation Unit Applied Tumor Immunity, National Center for Tumor Diseases, German Cancer Research Center, Heidelberg, Germany.; Department of Internal Medicine VI, University Hospital Heidelberg, Heidelberg, Germany., Halama N; Department of Translational Immunotherapy, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Medical oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.; Helmholtz Center for Translational Oncology (HITRON), Mainz, Germany.; Clinical Cooperation Unit Applied Tumor Immunity, National Center for Tumor Diseases, German Cancer Research Center, Heidelberg, Germany.; Department of Internal Medicine VI, University Hospital Heidelberg, Heidelberg, Germany.; Institute of Immunology, University Hospital Heidelberg, Heidelberg, Germany.

Publikováno v: Oncoimmunology [Oncoimmunology] 2019 Jul 13; Vol. 8 (9), pp. e1626193. Date of Electronic Publication: 2019 Jul 13 (Print Publication: 2019).

Understanding the Tumor Microenvironment in Melanoma Patients with In-Transit Metastases and Its Impacts on Immune Checkpoint Immunotherapy Responses.

Autor: Tian, Jiabao¹ (AUTHOR) jtia5428@uni.sydney.edu.au, Quek, Camelia¹ (AUTHOR) camelia.quek@sydney.edu.au

Publikováno v: International Journal of Molecular Sciences. Apr2024, Vol. 25 Issue 8, p4243. 16p.

Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment.

Autor: Ziogas, Dimitrios C.¹ (AUTHOR) ziogasdc@gmail.com, Theocharopoulos, Charalampos¹ (AUTHOR), Lialios, Panagiotis-Petros¹ (AUTHOR) hartheoch@gmail.com, Foteinou, Dimitra¹ (AUTHOR), Koumprentziotis, Ioannis-Alexios¹ (AUTHOR), Xynos, Georgios¹ (AUTHOR), Gogas, Helen¹ (AUTHOR) ziogasdc@gmail.com

Publikováno v: Cancers. May2023, Vol. 15 Issue 10, p2718. 32p.